John Richard Guyton | Scholars@Duke

John Richard Guyton
Professor of Medicine

Current research efforts focus on the role of niacin in clinical lipid practice. Despite the ending of a large clinical trial due to lack of benefit, niacin remains the second best lipid-modifying drug after statins. Why this trial did not replicate earlier success with niacin is a matter of great interest. Counterregulatory hormone responses may provide the answer. Another research focus is weight loss counseling in the busy clinic setting. Low glycemic dietary advice achieved average long-term weight loss of 3% (beyond 1 year) in a recently published study. One in four patients had long-term weight loss greater than 6%.

Dr. Guyton is recognized nationally as an expert in clinical management of lipid disorders and a leader in postgraduate education in this area. Both nationally and internationally, Dr. Guyton is known for his earlier work on lipid deposition in the arterial wall.

Key words: atherosclerosis, lipoproteins, statins, niacin, triglycerides, low density lipoproteins, high density lipoproteins

Current Appointments & Affiliations

Professor of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 2015
Assistant Professor of Pathology, Pathology, Clinical Science Departments 1994

Contact Information

281 Baker House, Brown Zone-Duke South, Durham, NC 27710
Duke Box 3510, Durham, NC 27710
john.guyton@duke.edu (919) 684-4821

Background
Education, Training, & Certifications
- Research Fellowship, Pathology, Harvard Medical School 1977 - 1979
- Resident, Medicine, UT Southwestern Medical School 1974 - 1976
- Intern, Medicine, UT Southwestern Medical School 1973 - 1974
- M.D., Harvard University 1973
- B.S., University of Mississippi 1969
Duke Appointment History
- Associate Professor of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 1993 - 2015
- Medical Center Instructor, Medicine, Clinical Science Departments 1992 - 1993
Recognition
In the News
- AUG 31, 2015 WTVD
  
  New cholesterol drug restores hope for patients
Research
Selected Grants
- EFC13786: Efficacy and Safety of Alirocumab in Patients with Primary Hypercholesterolemia not Treated with a Statin awarded by Sanofi US 2014 - 2018
- ODYSSEY OLE - LTS13463 : Open-Label Extension of EFC12492 and EFC12732 awarded by Sanofi US 2014 - 2018
- Lipoprotein Oxidation And Atherosclerosis awarded by National Institutes of Health 1991 - 1995
- Lipid-Rich Regions In Atherosclerosis awarded by National Institutes of Health 1993
- Arterial Wall And Lipid Deposition awarded by National Institutes of Health 1992 - 1993
External Relationships
- Amarin
- National Lipid Association
- Regeneron Pharmaceuticals
- Sanofi-Aventis
- The FH Foundation
- UpToDate
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Bornfeldt, Karin E., MacRae F. Linton, Edward A. Fisher, and John R. Guyton. “JCL roundtable: Lipids and inflammation in atherosclerosis.” J Clin Lipidol 15, no. 1 (January 2021): 3–17. https://doi.org/10.1016/j.jacl.2021.01.005.
    Full Text Link to Item
  - Guyton, John R. “From the editor: Rounding the corner.” J Clin Lipidol 15, no. 1 (January 2021): 1. https://doi.org/10.1016/j.jacl.2021.01.003.
    Full Text Link to Item
  - Guyton, John R. “From the editor: Moral choices and human health.” J Clin Lipidol 14, no. 6 (November 2020): 743–44. https://doi.org/10.1016/j.jacl.2020.10.002.
    Full Text Link to Item
  - Guyton, John R. “From the editor: Connectedness and lipidology.” J Clin Lipidol 14, no. 5 (September 2020): 611. https://doi.org/10.1016/j.jacl.2020.09.008.
    Full Text Link to Item
  - Connelly, Margery A., Jonathan Velez Rivera, John R. Guyton, Mohammad Shadab Siddiqui, and Arun J. Sanyal. “Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.” Aliment Pharmacol Ther 52, no. 4 (August 2020): 619–36. https://doi.org/10.1111/apt.15935.
    Full Text Link to Item
  - Langslet, Gisle, G Kees Hovingh, John R. Guyton, Marie T. Baccara-Dinet, Alexia Letierce, Garen Manvelian, and Michel Farnier. “Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study.” Cardiovasc Drugs Ther 34, no. 4 (August 2020): 515–23. https://doi.org/10.1007/s10557-020-06984-0.
    Full Text Link to Item
  - Boucher, Jackie L., Carol F. Kirkpatrick, David S. Ludwig, and John R. Guyton. “JCL roundtable: Low-carbohydrate diets.” J Clin Lipidol 14, no. 4 (July 2020): 384–95. https://doi.org/10.1016/j.jacl.2020.08.003.
    Full Text Link to Item
  - Guyton, John R. “From the editor: Never send to know for whom the bell tolls.” J Clin Lipidol 14, no. 4 (July 2020): 381–82. https://doi.org/10.1016/j.jacl.2020.08.001.
    Full Text Link to Item
  - Felando, Mary, Heather Rasmussen, Wahida Karmally, and John R. Guyton. “JCL roundtable: Healthy ethnic diets.” J Clin Lipidol 14, no. 3 (May 2020): 274–81. https://doi.org/10.1016/j.jacl.2020.05.006.
    Full Text Link to Item
  - Guyton, John R. “From the editor: Plagues and the ancient legacy of Epimenides.” J Clin Lipidol 14, no. 3 (May 2020): 271–72. https://doi.org/10.1016/j.jacl.2020.05.004.
    Full Text Link to Item
  - Guyton, John R. “From the editor: Confronting a pandemic or two.” J Clin Lipidol 14, no. 2 (March 2020): 159. https://doi.org/10.1016/j.jacl.2020.03.003.
    Full Text Link to Item
  - Kalra, Dinesh K., Geeta Sikand, Krishnaswami Vijayaraghavan, and John R. Guyton. “JCL roundtable: South Asian atherosclerotic risk.” J Clin Lipidol 14, no. 2 (March 2020): 161–69. https://doi.org/10.1016/j.jacl.2020.03.005.
    Full Text Link to Item
  - Bittner, Vera A., Terry A. Jacobson, Christie M. Ballantyne, and John R. Guyton. “JCL roundtable: Omega-3 fatty acids and cardiovascular outcomes.” J Clin Lipidol 14, no. 1 (January 2020): 4–15. https://doi.org/10.1016/j.jacl.2020.02.004.
    Full Text Link to Item
  - Guyton, John R. “From the editor: The "roaring Twenties" revisited?” J Clin Lipidol 14, no. 1 (January 2020): 1–2. https://doi.org/10.1016/j.jacl.2020.02.002.
    Full Text Link to Item
  - Moriarty, Patrick M., Paul D. Thompson, Christopher P. Cannon, John R. Guyton, Jean Bergeron, Franklin J. Zieve, Eric Bruckert, et al. “Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial.” J Clin Lipidol 14, no. 1 (January 2020): 88-97.e2. https://doi.org/10.1016/j.jacl.2020.01.001.
    Full Text Link to Item
  - Guyton, John R. “From the editor: Margaritaville blues and Philadelphia news.” J Clin Lipidol 13, no. 6 (November 2019): 857–58. https://doi.org/10.1016/j.jacl.2019.11.003.
    Full Text Link to Item
  - Duell, P Barton, Samuel S. Gidding, Rolf L. Andersen, Thomas Knickelbine, Lars Anderson, Eugenia Gianos, Peter Shrader, et al. “Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry.” Atherosclerosis 289 (October 2019): 85–93. https://doi.org/10.1016/j.atherosclerosis.2019.08.007.
    Full Text Link to Item
  - Guyton, John R. “From the editor: Considering less carbohydrate.” J Clin Lipidol 13, no. 5 (September 2019): 673–74. https://doi.org/10.1016/j.jacl.2019.10.008.
    Full Text Link to Item
  - Peterson, Amy L., Michele Mietus-Snyder, Don P. Wilson, and John R. Guyton. “JCL roundtable: Pediatric lipidology.” J Clin Lipidol 13, no. 5 (September 2019): 676–88. https://doi.org/10.1016/j.jacl.2019.10.010.
    Full Text Link to Item
  - Guyton, John R. “From the editor: Homeward bound?” J Clin Lipidol 13, no. 4 (July 2019): 509. https://doi.org/10.1016/j.jacl.2019.07.009.
    Full Text Link to Item
  - Liebeskind, Ann, Bruce A. Warden, Geeta Sikand, P Barton Duell, and John R. Guyton. “JCL Roundtable: Lipid clinic operations.” J Clin Lipidol 13, no. 4 (July 2019): 511–21. https://doi.org/10.1016/j.jacl.2019.07.011.
    Full Text Link to Item
  - Braun, Lynne T., Joseph J. Saseen, Carl E. Orringer, Neil J. Stone, and John R. Guyton. “JCL roundtable. The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: Process and product.” J Clin Lipidol 13, no. 3 (May 2019): 345–55. https://doi.org/10.1016/j.jacl.2019.05.008.
    Full Text Link to Item
  - Guyton, John R. “From the editor: Atherosclerosis in different flavors.” J Clin Lipidol 13, no. 3 (May 2019): 341–42. https://doi.org/10.1016/j.jacl.2019.05.007.
    Full Text Link to Item
  - Friedrich, Debra A., Dean G. Karalis, Karen E. Aspry, Seth S. Martin, and John R. Guyton. “JCL roundtable: Lipid treatment targets.” J Clin Lipidol 13, no. 2 (March 2019): 223–30. https://doi.org/10.1016/j.jacl.2019.04.003.
    Full Text Link to Item
  - Guyton, John R. “From the editor: New ACC/AHA/Multisociety Cholesterol Guidelines.” J Clin Lipidol 13, no. 2 (March 2019): 219–20. https://doi.org/10.1016/j.jacl.2019.04.001.
    Full Text Link to Item
  - Alexopoulos, Anastasia-Stefania, Ali Qamar, Kathryn Hutchins, Matthew J. Crowley, Bryan C. Batch, and John R. Guyton. “Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes.” Curr Diab Rep 19, no. 4 (February 26, 2019): 13. https://doi.org/10.1007/s11892-019-1136-3.
    Full Text Link to Item
  - Dufour, Robert, G Kees Hovingh, John R. Guyton, Gisle Langslet, Marie T. Baccara-Dinet, Chantal Din-Bell, Garen Manvelian, and Michel Farnier. “Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial.” J Clin Lipidol 13, no. 1 (January 2019): 138–47. https://doi.org/10.1016/j.jacl.2018.11.007.
    Full Text Link to Item
  - Gill, Edward A., Michael J. Blaha, and John R. Guyton. “JCL roundtable: Coronary artery calcium scoring and other vascular imaging for risk assessment.” J Clin Lipidol 13, no. 1 (January 2019): 4–14. https://doi.org/10.1016/j.jacl.2019.01.008.
    Full Text Link to Item
  - Guyton, John R. “From the editor: Humans are animals and therefore make saturated fat.” J Clin Lipidol 13, no. 1 (January 2019): 1–2. https://doi.org/10.1016/j.jacl.2019.01.001.
    Full Text Link to Item
  - Farnier, Michel, G Kees Hovingh, Gisle Langslet, Robert Dufour, Marie T. Baccara-Dinet, Chantal Din-Bell, Garen Manvelian, and John R. Guyton. “Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program.” Atherosclerosis 278 (November 2018): 307–14. https://doi.org/10.1016/j.atherosclerosis.2018.08.036.
    Full Text Link to Item
  - Guyton, John R. “From the editor: Lessons from the East.” J Clin Lipidol 12, no. 6 (November 2018): 1331–32. https://doi.org/10.1016/j.jacl.2018.11.001.
    Full Text Link to Item
  - Hovingh, G Kees, John R. Guyton, Gisle Langslet, Robert Dufour, Marie T. Baccara-Dinet, Chantal Din-Bell, Garen Manvelian, and Michel Farnier. “Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia.” J Clin Lipidol 12, no. 6 (November 2018): 1463–70. https://doi.org/10.1016/j.jacl.2018.08.011.
    Full Text Link to Item
  - Marcovina, Santica M., Patrick M. Moriarty, Marlys L. Koschinsky, and John R. Guyton. “JCL roundtable-Lipoprotein(a): The emerging risk factor.” J Clin Lipidol 12, no. 6 (November 2018): 1335–45. https://doi.org/10.1016/j.jacl.2018.11.003.
    Full Text Link to Item
  - Brinton, Eliot A., Christie M. Ballantyne, John R. Guyton, Sephy Philip, Ralph T. Doyle, Rebecca A. Juliano, and Lori Mosca. “Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.” J Womens Health (Larchmt) 27, no. 9 (September 2018): 1170–76. https://doi.org/10.1089/jwh.2017.6757.
    Full Text Link to Item
  - Cuchel, Marina, Anand Rohatgi, Frank M. Sacks, and John R. Guyton. “JCL roundtable: High-density lipoprotein function and reverse cholesterol transport.” J Clin Lipidol 12, no. 5 (September 2018): 1086–94. https://doi.org/10.1016/j.jacl.2018.09.005.
    Full Text Link to Item
  - Guyton, John R. “From the editor: What is the bottom line for clinical lipidology research?” J Clin Lipidol 12, no. 5 (September 2018): 1083–84. https://doi.org/10.1016/j.jacl.2018.09.004.
    Full Text Link to Item
  - Bittner, Vera A., Robert P. Giugliano, Eliot A. Brinton, and John R. Guyton. “PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease.” J Clin Lipidol 12, no. 4 (July 2018): 835–43. https://doi.org/10.1016/j.jacl.2018.06.013.
    Full Text Link to Item
  - Guyton, John R. “From the editor: O Canada! A tariff-free zone for scientific exchange.” J Clin Lipidol 12, no. 4 (July 2018): 831–32. https://doi.org/10.1016/j.jacl.2018.06.014.
    Full Text Link to Item
  - Guyton, John R. “Old news and a new order.” J Clin Lipidol 12, no. 3 (May 2018): 571. https://doi.org/10.1016/j.jacl.2018.05.005.
    Full Text Link to Item
  - Severson, Tracy, Penny M. Kris-Etherton, Jennifer G. Robinson, and John R. Guyton. “Roundtable discussion: Dietary fats in prevention of atherosclerotic cardiovascular disease.” J Clin Lipidol 12, no. 3 (May 2018): 574–82. https://doi.org/10.1016/j.jacl.2018.05.006.
    Full Text Link to Item
  - Guyton, John R. “From the editor: Weighing the advantages of lipid conference and journal.” J Clin Lipidol 12, no. 2 (March 2018): 251–52. https://doi.org/10.1016/j.jacl.2018.03.001.
    Full Text Link to Item
  - Otvos, James D., John R. Guyton, Margery A. Connelly, Sydney Akapame, Vera Bittner, Steven L. Kopecky, Megan Lacy, Santica M. Marcovina, Joseph B. Muhlestein, and William E. Boden. “Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.” J Clin Lipidol 12, no. 2 (March 2018): 348-355.e2. https://doi.org/10.1016/j.jacl.2018.01.002.
    Full Text Link to Item
  - Guyton, John R. “From the editor: A run of success in treating atherosclerotic vascular disease.” J Clin Lipidol 12, no. 1 (January 2018): 1–2. https://doi.org/10.1016/j.jacl.2017.12.016.
    Full Text Link to Item
  - Amrock, Stephen M., P Barton Duell, Thomas Knickelbine, Seth S. Martin, Emily C. O’Brien, Karol E. Watson, Joanna Mitri, et al. “Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry.” Atherosclerosis 267 (December 2017): 19–26. https://doi.org/10.1016/j.atherosclerosis.2017.10.006.
    Full Text Link to Item
  - Guyton, John R. “From the Editor.” J Clin Lipidol 11, no. 6 (November 2017): 1297. https://doi.org/10.1016/j.jacl.2017.10.025.
    Full Text Link to Item
  - Superko, Harold Robert, Xue-Qiao Zhao, Howard N. Hodis, and John R. Guyton. “Niacin and heart disease prevention: Engraving its tombstone is a mistake.” J Clin Lipidol 11, no. 6 (November 2017): 1309–17. https://doi.org/10.1016/j.jacl.2017.08.005.
    Full Text Link to Item
  - Guyton, John R. “Marine omega-3 fatty acids and cardiac death.” J Clin Lipidol 11, no. 5 (September 2017): 1124–25. https://doi.org/10.1016/j.jacl.2017.08.009.
    Full Text Link to Item
  - Guyton, John R. “From the Editor.” J Clin Lipidol 11, no. 5 (September 2017): 1109. https://doi.org/10.1016/j.jacl.2017.08.012.
    Full Text Link to Item
  - Sabatine, Marc S., Robert P. Giugliano, Anthony C. Keech, Narimon Honarpour, Stephen D. Wiviott, Sabina A. Murphy, Julia F. Kuder, et al. “Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.” N Engl J Med 376, no. 18 (May 4, 2017): 1713–22. https://doi.org/10.1056/NEJMoa1615664.
    Full Text Link to Item
  - Mosca, Lori, Christie M. Ballantyne, Harold E. Bays, John R. Guyton, Sephy Philip, Ralph T. Doyle, and Rebecca A. Juliano. “Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials).” Am J Cardiol 119, no. 3 (February 1, 2017): 397–403. https://doi.org/10.1016/j.amjcard.2016.10.027.
    Full Text Link to Item
  - Gann, D. S., F. E. Yates, D. J. Marsh, S. W. Smith, M. Ookhtens, R. N. Bergman, E. W. Kraegen, et al. “REGULATION AND CONTROL IN PHYSIOLOGICAL SYSTEMS.,” January 1, 2017.
  - Ginsberg, Henry N., Daniel J. Rader, Frederick J. Raal, John R. Guyton, Marie T. Baccara-Dinet, Christelle Lorenzato, Robert Pordy, and Erik Stroes. “Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.” Cardiovasc Drugs Ther 30, no. 5 (October 2016): 473–83. https://doi.org/10.1007/s10557-016-6685-y.
    Full Text Link to Item
  - Stroes, Erik, John R. Guyton, Norman Lepor, Fernando Civeira, Daniel Gaudet, Gerald F. Watts, Marie T. Baccara-Dinet, et al. “Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.” J Am Heart Assoc 5, no. 9 (September 13, 2016). https://doi.org/10.1161/JAHA.116.003421.
    Full Text Link to Item
  - Goldberg, Ronald B., Vera A. Bittner, Richard L. Dunbar, Jerome L. Fleg, George Grunberger, John R. Guyton, Lawrence A. Leiter, et al. “Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH.” Am J Med 129, no. 7 (July 2016): 753.e13-753.e22. https://doi.org/10.1016/j.amjmed.2016.02.039.
    Full Text Link to Item
  - Lakey, Wanda C., Nicole G. Greyshock, Carly E. Kelley, Mohammad A. Siddiqui, Umar Ahmad, Yuliya V. Lokhnygina, and John R. Guyton. “Statin intolerance in a referral lipid clinic.” J Clin Lipidol 10, no. 4 (July 2016): 870-879.e3. https://doi.org/10.1016/j.jacl.2016.03.004.
    Full Text Link to Item
  - Maki, Kevin C., John R. Guyton, Carl E. Orringer, Ian Hamilton-Craig, Dominik D. Alexander, and Michael H. Davidson. “Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia.” J Clin Lipidol 10, no. 4 (July 2016): 905–14. https://doi.org/10.1016/j.jacl.2016.03.008.
    Full Text Link to Item
  - Moriarty, Patrick M., Paul D. Thompson, Christopher P. Cannon, John R. Guyton, Jean Bergeron, Franklin J. Zieve, Eric Bruckert, et al. “Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.” J Clin Lipidol 9, no. 6 (November 2015): 758–69. https://doi.org/10.1016/j.jacl.2015.08.006.
    Full Text Link to Item
  - Naggie, Susanna, Keyur Patel, Lan-Yan Yang, Shein-Chung Chow, Victoria Johnson, John R. Guyton, Andrew J. Muir, Mark Sulkowski, and Charles Hicks. “Antiretroviral Effects on Host Lipoproteins Are Associated With Changes in Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency Virus/HCV Coinfected Individuals.” Open Forum Infect Dis 2, no. 2 (April 2015): ofv066. https://doi.org/10.1093/ofid/ofv066.
    Full Text Link to Item
  - Santos, Raul D., P Barton Duell, Cara East, John R. Guyton, Patrick M. Moriarty, Wai Chin, and Robert S. Mittleman. “Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension.” Eur Heart J 36, no. 9 (March 1, 2015): 566–75. https://doi.org/10.1093/eurheartj/eht549.
    Full Text Link to Item
  - Moriarty, Patrick M., Terry A. Jacobson, Eric Bruckert, Paul D. Thompson, John R. Guyton, Marie T. Baccara-Dinet, and Daniel Gipe. “Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial.” J Clin Lipidol 8, no. 6 (November 2014): 554–61. https://doi.org/10.1016/j.jacl.2014.09.007.
    Full Text Link to Item
  - McDonnell, Donald P., Sunghee Park, Matthew T. Goulet, Jeff Jasper, Suzanne E. Wardell, Ching-Yi Chang, John D. Norris, John R. Guyton, and Erik R. Nelson. “Obesity, cholesterol metabolism, and breast cancer pathogenesis.” Cancer Res 74, no. 18 (September 15, 2014): 4976–82. https://doi.org/10.1158/0008-5472.CAN-14-1756.
    Full Text Link to Item
  - Guyton, John R., Harold E. Bays, Scott M. Grundy, Terry A. Jacobson, and Terry A. The National Lipid Association Statin Intolerance Panel. “An assessment by the Statin Intolerance Panel: 2014 update.” J Clin Lipidol 8, no. 3 Suppl (May 2014): S72–81. https://doi.org/10.1016/j.jacl.2014.03.002.
    Full Text Link to Item
  - Guyton, John R., Kristen B. Campbell, and Wanda C. Lakey. “Statin intolerance: more questions than answers.” Expert Rev Clin Pharmacol 7, no. 1 (January 2014): 1–3. https://doi.org/10.1586/17512433.2014.857601.
    Full Text Link to Item
  - Guyton, John R. “MR spectroscopy of cholesteryl ester in human atherosclerosis.” Jacc Cardiovasc Imaging 6, no. 12 (December 2013): 1285–86. https://doi.org/10.1016/j.jcmg.2013.04.018.
    Full Text Link to Item
  - Okorodudu, Daniel E., Matthew J. Crowley, Siby Sebastian, Jennifer V. Rowell, and John R. Guyton. “Inherited lipemic splenomegaly and the spectrum of apolipoprotein E p.Leu167del mutation phenotypic variation.” J Clin Lipidol 7, no. 6 (November 2013): 566–72. https://doi.org/10.1016/j.jacl.2013.09.003.
    Full Text Link to Item
  - Guyton, John R., April E. Slee, Todd Anderson, Jerome L. Fleg, Ronald B. Goldberg, Moti L. Kashyap, Santica M. Marcovina, et al. “Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).” J Am Coll Cardiol 62, no. 17 (October 22, 2013): 1580–84. https://doi.org/10.1016/j.jacc.2013.07.023.
    Full Text Link to Item
  - Farnier, Michel, John R. Guyton, Erin Jensen, Adam B. Polis, Amy O. Johnson-Levonas, and Philippe Brudi. “Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.” Atherosclerosis 229, no. 2 (August 2013): 415–22. https://doi.org/10.1016/j.atherosclerosis.2013.05.010.
    Full Text Link to Item
  - Cziraky, Mark J., Vincent J. Willey, James M. McKenney, Siddhesh A. Kamat, Maxine D. Fisher, John R. Guyton, Terry A. Jacobson, and Michael H. Davidson. “Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting.” J Clin Lipidol 7, no. 2 (March 2013): 102–8. https://doi.org/10.1016/j.jacl.2012.06.006.
    Full Text Link to Item
  - Keating, Alyssa J., Kristen Bova Campbell, and John R. Guyton. “Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy.” Ann Pharmacother 47, no. 3 (March 2013): 398–404. https://doi.org/10.1345/aph.1R509.
    Full Text Link to Item
  - Lakey, Wanda C., Nicole Greyshock, and John R. Guyton. “Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrants.” J Clin Lipidol 7, no. 2 (March 2013): 178–81. https://doi.org/10.1016/j.jacl.2012.11.002.
    Full Text Link to Item
  - Chiba-Falek, Ornit, Colton Linnertz, John Guyton, Stephen D. Gardner, Allen D. Roses, Jeanette J. McCarthy, and Keyur Patel. “Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection.” Hum Genet 131, no. 12 (December 2012): 1911–20. https://doi.org/10.1007/s00439-012-1220-0.
    Full Text Link to Item
  - Guyton, John R., Sergio Fazio, Adeniyi J. Adewale, Erin Jensen, Joanne E. Tomassini, Arvind Shah, and Andrew M. Tershakovec. “Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial.” Diabetes Care 35, no. 4 (April 2012): 857–60. https://doi.org/10.2337/dc11-1369.
    Full Text Link to Item
  - Rowell, J., A. J. Thompson, J. R. Guyton, X. Q. Lao, J. G. McHutchison, J. J. McCarthy, and K. Patel. “Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis.” Hepatol Int 6, no. 2 (April 2012): 475–81. https://doi.org/10.1007/s12072-011-9291-x.
    Full Text Link to Item
  - Rajanna, Veena, Kristen B. Campbell, Jeffrey Leimberger, Bibhu D. Mohanty, and John R. Guyton. “Elevation of fasting morning glucose relative to hemoglobin A1c in normoglycemic patients treated with niacin and with statins.” J Clin Lipidol 6, no. 2 (March 2012): 168–73. https://doi.org/10.1016/j.jacl.2011.12.008.
    Full Text Link to Item
  - Leiter, L. A., D. J. Betteridge, M. Farnier, J. R. Guyton, J. Lin, A. Shah, A. O. Johnson-Levonas, and P. Brudi. “Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.” Diabetes Obes Metab 13, no. 7 (July 2011): 615–28. https://doi.org/10.1111/j.1463-1326.2011.01383.x.
    Full Text Link to Item
  - Guyton, John R., D John Betteridge, Michel Farnier, Lawrence A. Leiter, Jianxin Lin, Arvind Shah, Amy O. Johnson-Levonas, and Philippe Brudi. “Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes.” Diab Vasc Dis Res 8, no. 2 (April 2011): 160–72. https://doi.org/10.1177/1479164111406457.
    Full Text Link to Item
  - Roberts, William C., Antonio M. Gotto, John Guyton, John LaRosa, and Ronald Viggiani. “The editor's roundtable: Closing the clinical practice gap-using evidence-based treatments for managing lipids.” Am J Cardiol 107, no. 2 (January 15, 2011): 230–42. https://doi.org/10.1016/j.amjcard.2010.09.023.
    Full Text Link to Item
  - Benjamin, Ashlee M., Sunil Suchindran, Kaela Pearce, Jennifer Rowell, Lillian F. Lien, John R. Guyton, and Jeanette J. McCarthy. “Gene by sex interaction for measures of obesity in the framingham heart study.” J Obes 2011 (2011): 329038. https://doi.org/10.1155/2011/329038.
    Full Text Link to Item
  - Bailey, Westly A., Eric C. Westman, Megan L. Marquart, and John R. Guyton. “Low glycemic diet for weight loss in hypertriglyceridemic patients attending a lipid clinic.” J Clin Lipidol 4, no. 6 (November 2010): 508–14. https://doi.org/10.1016/j.jacl.2010.08.019.
    Full Text Link to Item
  - Fazio, S., J. R. Guyton, J. Lin, J. E. Tomassini, A. Shah, and A. M. Tershakovec. “Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome.” Diabetes Obes Metab 12, no. 11 (November 2010): 983–93. https://doi.org/10.1111/j.1463-1326.2010.01289.x.
    Full Text Link to Item
  - Guyton, John R. “Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?” Curr Opin Lipidol 21, no. 4 (August 2010): 372–77. https://doi.org/10.1097/MOL.0b013e32833c1f16.
    Full Text Link to Item
  - Li, Josephine H., Xiang Qian Lao, Hans L. Tillmann, Jennifer Rowell, Keyur Patel, Alexander Thompson, Sunil Suchindran, et al. “Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.” Hepatology 51, no. 6 (June 2010): 1904–11. https://doi.org/10.1002/hep.23592.
    Full Text Link to Item
  - Goldberg, Ronald B., John R. Guyton, Theodore Mazzone, Ruth S. Weinstock, Adam B. Polis, Diane Tipping, Joanne E. Tomassini, and Andrew M. Tershakovec. “Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia.” Diabetes Care 33, no. 5 (May 2010): 1021–24. https://doi.org/10.2337/dc09-1762.
    Full Text Link to Item
  - Suchindran, Sunil, David Rivedal, John R. Guyton, Tom Milledge, Xiaoyi Gao, Ashlee Benjamin, Jennifer Rowell, Geoffrey S. Ginsburg, and Jeanette J. McCarthy. “Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study.” Plos Genet 6, no. 4 (April 29, 2010): e1000928. https://doi.org/10.1371/journal.pgen.1000928.
    Full Text Open Access Copy Link to Item
  - Fazio, Sergio, John R. Guyton, Adam B. Polis, Adeniyi J. Adewale, Joanne E. Tomassini, Nicholas W. Ryan, and Andrew M. Tershakovec. “Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.” Am J Cardiol 105, no. 4 (February 15, 2010): 487–94. https://doi.org/10.1016/j.amjcard.2009.10.001.
    Full Text Link to Item
  - Chiba-Falek, Ornit, Marshall Nichols, Sunil Suchindran, John Guyton, Geoffrey S. Ginsburg, Elizabeth Barrett-Connor, and Jeanette J. McCarthy. “Impact of gene variants on sex-specific regulation of human Scavenger receptor class B type 1 (SR-BI) expression in liver and association with lipid levels in a population-based study.” Bmc Med Genet 11 (January 19, 2010): 9. https://doi.org/10.1186/1471-2350-11-9.
    Full Text Open Access Copy Link to Item
  - Forman, Eric J., John R. Guyton, Stanley J. Filip, and Thomas M. Price. “Implanted estrogen pellets associated with hypertriglyceridemia, biliary dyskinesia and focal nodular hyperplasia of the liver: a case report.” J Reprod Med 55, no. 1–2 (January 2010): 87–90.
    Link to Item
  - Brown, B. G., P. L. Canner, M. E. McGovern, J. R. Guyton, and L. A. Carlson. “Nicotinic Acid,” December 1, 2009, 298–314. https://doi.org/10.1016/B978-141605469-6.50029-9.
    Full Text
  - Guyton, J. R., and A. C. Goldberg. “Bile Acid Sequestrants,” December 1, 2009, 281–87. https://doi.org/10.1016/B978-141605469-6.50027-5.
    Full Text
  - Fazio, S., J. R. Guyton, J. Lin, J. E. Tomassini, A. Shah, and A. M. Tershakovec. “Long-term ezetimibe/simvastatin (E/S) plus extended release niacin (N) treatment in hyperlipidaemic patients with diabetes and metabolic syndrome.” Diabetologia 52 (September 1, 2009): S483–S483.
    Link to Item
  - Tomassini, J. E., T. Mazzone, R. B. Goldberg, J. R. Guyton, R. S. Weinstock, A. Polis, E. Jensen, and A. M. Tershakovec. “Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia.” Diabetes Obes Metab 11, no. 9 (September 2009): 855–64. https://doi.org/10.1111/j.1463-1326.2009.01061.x.
    Full Text Link to Item
  - Brown, W Virgil, Anne C. Goldberg, John R. Guyton, and Robert H. Knopp. “The use of niacin.” J Clin Lipidol 3, no. 2 (April 2009): 65–69. https://doi.org/10.1016/j.jacl.2009.02.010.
    Full Text Link to Item
  - Guyton, John R., and Phillip D. Simmons. “Flushing and other dermatologic adverse events associated with extended-release niacin therapy.” J Clin Lipidol 3, no. 2 (April 2009): 101–8. https://doi.org/10.1016/j.jacl.2009.02.003.
    Full Text Link to Item
  - Brown, W Virgil, Luther Clark, James M. Falko, John R. Guyton, Tomas J. Rees, Gustav Schonfeld, and Maria F. Lopes-Virella. “Optimal management of lipids in diabetes and metabolic syndrome.” J Clin Lipidol 2, no. 5 (October 2008): 335–42. https://doi.org/10.1016/j.jacl.2008.08.444.
    Full Text Link to Item
  - Fazio, S., B. G. Brown, J. R. Guyton, A. Polis, J. Tomassini, and A. M. Tershakovec. “Triple combination Ezetimibe/Simvastatin plus extended release Niacin therapy improves ratios of ApoB/ApoA-I containing lipoproteins in hyperlipidemia patients.” European Heart Journal 29 (September 1, 2008): 345–46.
    Link to Item
  - Friedewald, Vincent E., Christie M. Ballantyne, Michael H. Davidson, John R. Guyton, and William C. Roberts. “The editor's roundtable: lipid management beyond statins-reducing residual cardiovascular risk.” Am J Cardiol 102, no. 5 (September 1, 2008): 559–67. https://doi.org/10.1016/j.amjcard.2008.06.028.
    Full Text Link to Item
  - Lien, Lillian F., and John R. Guyton. “Metabolic syndrome.” Dermatol Ther 21, no. 5 (September 2008): 362–75. https://doi.org/10.1111/j.1529-8019.2008.00218.x.
    Full Text Link to Item
  - Tomassini, J. E., T. Mazzone, R. B. Goldberg, J. R. Guyton, R. S. Weinstock, A. Polis, and A. M. Tershakovec. “Effect of ezctimibe/sinivastatin (E/S) versus atorvastatin (A) on lipoprotein subclasses in type 2 diabetes (T2DM) patients with hypercholesterolaemia (HC).” Diabetologia 51 (September 1, 2008): S339–S339.
    Link to Item
  - Brown, B. G., S. Fazio, J. R. Guyton, A. Polis, J. E. Tomassini, and A. M. Tershakovec. “TIME AND DOSE-RELATED EFFECTS ON THE LIPID PROFILE IN HYPERLIPIDEMIA PATIENTS FOLLOWING TRIPLE COMBINATION THERAPY WITH EZETIMIBE/SIMVASTATIN + NIACIN.” Atherosclerosis Supplements 9, no. 1 (May 2008): 186–87. https://doi.org/10.1016/s1567-5688(08)70749-9.
    Full Text
  - FAZIO, S., B. BROWN, J. GUYTON, A. POLIS, J. TOMASSINI, and A. TERSHAKOVEC. “EFFICACY AND SAFETY OF EZETIMIBE/SIMVASTATIN COADMINISTERED WITH EXTENDED RELEASE NIACIN IN PATIENTS WITH TYPE IIA OR IIB HYPERLIPIDEMIA.” Atherosclerosis Supplements 9, no. 1 (May 2008): 16–16. https://doi.org/10.1016/s1567-5688(08)70058-8.
    Full Text
  - Guyton, J. R., B. G. Brown, S. Fazio, A. Polis, J. E. Tomassini, and A. M. Tershakovec. “SAFETY AND TOLERABILITY OF THE TRIPLE COMBINATION EZETIMIBE/SIMVASTATIN + EXTENDED RELEASE NIACIN IN HYPERLIPIDEMIA PATIENTS.” Atherosclerosis Supplements 9, no. 1 (May 2008): 261–261. https://doi.org/10.1016/s1567-5688(08)71051-1.
    Full Text
  - Guyton, John R., B Greg Brown, Sergio Fazio, Adam Polis, Joanne E. Tomassini, and Andrew M. Tershakovec. “Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.” J Am Coll Cardiol 51, no. 16 (April 22, 2008): 1564–72. https://doi.org/10.1016/j.jacc.2008.03.003.
    Full Text Link to Item
  - Guyton, John R., Ronald B. Goldberg, Theodore Mazzone, Ruth S. Weinstock, Adam Polis, Elizabeth Rosenberg, and Andrew M. Tershakovec. “Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes.” J Clin Lipidol 2, no. 1 (February 2008): 19–24. https://doi.org/10.1016/j.jacl.2007.12.004.
    Full Text Link to Item
  - Weinstock, Ruth S., Ronald B. Goldberg, John R. Guyton, Theodore Mazzone, Adam Polis, Joanne E. Tomassini, Jianxin Lin, Arvind Shah, and Andrew M. Tershakovec. “Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes.” J Clin Lipidol 2, no. 1 (February 2008): 25–35. https://doi.org/10.1016/j.jacl.2008.01.001.
    Full Text Link to Item
  - Guyton, John R. “Niacin in cardiovascular prevention: mechanisms, efficacy, and safety.” Curr Opin Lipidol 18, no. 4 (August 2007): 415–20. https://doi.org/10.1097/MOL.0b013e3282364add.
    Full Text Link to Item
  - Wang, Haichen, John R. Lynch, Pingping Song, Hyuk-Jun Yang, Robert B. Yates, Brian Mace, David S. Warner, John R. Guyton, and Daniel T. Laskowitz. “Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury.” Exp Neurol 206, no. 1 (July 2007): 59–69. https://doi.org/10.1016/j.expneurol.2007.03.031.
    Full Text Link to Item
  - Guyton, John R., and Harold E. Bays. “Safety considerations with niacin therapy.” Am J Cardiol 99, no. 6A (March 19, 2007): 22C-31C. https://doi.org/10.1016/j.amjcard.2006.11.018.
    Full Text Link to Item
  - Jacobson, Terry A., Annemarie Armani, James M. McKenney, and John R. Guyton. “Safety considerations with gastrointestinally active lipid-lowering drugs.” Am J Cardiol 99, no. 6A (March 19, 2007): 47C-55C. https://doi.org/10.1016/j.amjcard.2006.11.022.
    Full Text Link to Item
  - Goldberg, R. B., J. R. Guyton, T. Mazzone, R. S. Weinstock, A. Polis, P. Edwards, J. E. Tomassini, and A. M. Tershakovec. “In reply [6].” Mayo Clinic Proceedings 82, no. 4 (January 1, 2007): 522. https://doi.org/10.4065/82.4.522.
    Full Text
  - Goldberg, Ronald B., John R. Guyton, Theodore Mazzone, Ruth S. Weinstock, Adam Polis, Patricia Edwards, Joanne E. Tomassini, and Andrew M. Tershakovec. “Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.” Mayo Clin Proc 81, no. 12 (December 2006): 1579–88. https://doi.org/10.4065/81.12.1579.
    Full Text Link to Item
  - Guyton, John R., Ronald B. Goldberg, Theodore Mazzone, Ruth S. Weinstock, Adam Polis, Elizabeth Rosenberg, Patricia Edwards, and Andrew M. Tershakovec. “Ezetimibe/simvastatin more favorably influences lipoprotein/apolipoprotein ratios than atorvastatin monotherapy in patients with type 2 diabetes.” Circulation 114, no. 18 (October 31, 2006): 797–797.
    Link to Item
  - Weinstock, Ruth S., Ronald B. Goldberg, John R. Guyton, Theodore Mazzone, Adam Polis, Joanne E. Tomassini, Elizabeth Desrosiers, and Andrew M. Tershakovec. “Enhanced attainment of optional recommended levels of LDL-C, apolipoprotein B, non-HDL and hsCRP in type 2 diabetes patients treated with ezetimibe/simvastatin compared to atorvastatin.” Circulation 114, no. 18 (October 31, 2006): 796–97.
    Link to Item
  - Goldstein, Larry B., Robert Adams, Mark J. Alberts, Lawrence J. Appel, Lawrence M. Brass, Cheryl D. Bushnell, Antonio Culebras, et al. “Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group.” Circulation 113, no. 24 (June 20, 2006): e873–923. https://doi.org/10.1161/01.STR.0000223048.70103.F1.
    Full Text Link to Item
  - Westman, Eric C., William S. Yancy, Maren K. Olsen, Tara Dudley, and John R. Guyton. “Effect of a low-carbohydrate, ketogenic diet program compared to a low-fat diet on fasting lipoprotein subclasses.” Int J Cardiol 110, no. 2 (June 16, 2006): 212–16. https://doi.org/10.1016/j.ijcard.2005.08.034.
    Full Text Link to Item
  - Anderson, J. J. B., S. A. Prytherch, M. Sparling, C. Barrett, and J. R. Guyton. “The metabolic syndrome: A common hyperinsulinemic disorder with severe health effects.” Nutrition Today 41, no. 3 (May 1, 2006): 115–22. https://doi.org/10.1097/00017285-200605000-00007.
    Full Text
  - Cziraky, Mark J., Vincent J. Willey, James M. McKenney, Siddhesh A. Kamat, Maxine D. Fisher, John R. Guyton, Terry A. Jacobson, and Michael H. Davidson. “Statin safety: an assessment using an administrative claims database.” Am J Cardiol 97, no. 8A (April 17, 2006): 61C-68C. https://doi.org/10.1016/j.amjcard.2005.12.011.
    Full Text Link to Item
  - Guyton, John R. “Benefit versus risk in statin treatment.” Am J Cardiol 97, no. 8A (April 17, 2006): 95C-97C. https://doi.org/10.1016/j.amjcard.2005.12.016.
    Full Text Link to Item
  - McKenney, James M., Michael H. Davidson, Terry A. Jacobson, John R. Guyton, and John R. National Lipid Association Statin Safety Assessment Task Force. “Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.” Am J Cardiol 97, no. 8A (April 17, 2006): 89C-94C. https://doi.org/10.1016/j.amjcard.2006.02.030.
    Full Text Link to Item
  - Jelesoff, Nicole E., Christie M. Ballantyne, Antonios M. Xydakis, Philip Chiou, Peter H. Jones, and John R. Guyton. “Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia.” Endocr Pract 12, no. 2 (March 2006): 159–64. https://doi.org/10.4158/EP.12.2.159.
    Full Text Link to Item
  - Miranda, Phillippa J., Ralph A. DeFronzo, Robert M. Califf, and John R. Guyton. “Metabolic syndrome: definition, pathophysiology, and mechanisms.” Am Heart J 149, no. 1 (January 2005): 33–45. https://doi.org/10.1016/j.ahj.2004.07.013.
    Full Text Link to Item
  - Miranda, Phillippa J., Ralph A. DeFronzo, Robert M. Califf, and John R. Guyton. “Metabolic syndrome: evaluation of pathological and therapeutic outcomes.” Am Heart J 149, no. 1 (January 2005): 20–32. https://doi.org/10.1016/j.ahj.2004.07.012.
    Full Text Link to Item
  - Xydakis, Antonios M., John R. Guyton, Philip Chiou, Judy L. Stein, Peter H. Jones, and Christie M. Ballantyne. “Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia.” Am J Cardiol 94, no. 6 (September 15, 2004): 795–97. https://doi.org/10.1016/j.amjcard.2004.06.008.
    Full Text Link to Item
  - Guyton, John R. “Extended-release niacin for modifying the lipoprotein profile.” Expert Opin Pharmacother 5, no. 6 (June 2004): 1385–98. https://doi.org/10.1517/14656566.5.6.1385.
    Full Text Link to Item
  - Yancy, William S., Maren K. Olsen, John R. Guyton, Ronna P. Bakst, and Eric C. Westman. “A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial.” Ann Intern Med 140, no. 10 (May 18, 2004): 769–77. https://doi.org/10.7326/0003-4819-140-10-200405180-00006.
    Full Text Link to Item
  - Waters, David D., John R. Guyton, David M. Herrington, Mary P. McGowan, Nanette K. Wenger, Charles Shear, and Charles TNT Steering Committee Members and Investigators. “Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?” Am J Cardiol 93, no. 2 (January 15, 2004): 154–58. https://doi.org/10.1016/j.amjcard.2003.09.031.
    Full Text Link to Item
  - Duvall, W Lane, Michael A. Blazing, Shilpa Saxena, and John R. Guyton. “Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.” J Cardiovasc Risk 9, no. 6 (December 2002): 339–47. https://doi.org/10.1097/01.hjr.0000044518.34172.72.
    Full Text Link to Item
  - Guyton, John R. “Clinical assessment of atherosclerotic lesions: emerging from angiographic shadows.” Circulation 106, no. 11 (September 10, 2002): 1308–9. https://doi.org/10.1161/01.cir.0000030315.80547.3f.
    Full Text Link to Item
  - Kashyap, Moti L., Mark E. McGovern, Kathleen Berra, John R. Guyton, Peter O. Kwiterovich, Wayne L. Harper, Phillip D. Toth, et al. “Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.” Am J Cardiol 89, no. 6 (March 15, 2002): 672–78. https://doi.org/10.1016/s0002-9149(01)02338-4.
    Full Text Link to Item
  - Duvall, W. L., M. A. Blazing, S. Saxena, and J. R. Guyton. “Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin–niacin combination therapy.” European Journal of Cardiovascular Prevention &Amp; Rehabilitation 9, no. 6 (January 1, 2002): 339–47. https://doi.org/10.1177/174182670200900607.
    Full Text
  - Yancy, W. S., J. R. Guyton, R. P. Bakst, K. F. Tomlin, W. H. Bryson, C. E. Perkins, and E. C. Westman. “A randomized controlled trial of a very-low-carbohydrate diet with nutritional supplements versus a low-fat/low-calorie diet.” Obesity Research 9 (September 1, 2001): 184S-184S.
    Link to Item
  - Guyton, J. R. “Phospholipid hydrolytic enzymes in a 'cesspool' of arterial intimal lipoproteins: a mechanism for atherogenic lipid accumulation.” Arterioscler Thromb Vasc Biol 21, no. 6 (June 2001): 884–86. https://doi.org/10.1161/01.atv.21.6.884.
    Full Text Link to Item
  - Goldberg, A., P. Alagona, D. M. Capuzzi, J. Guyton, J. M. Morgan, J. Rodgers, R. Sachson, and P. Samuel. “Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia.” Am J Cardiol 85, no. 9 (May 1, 2000): 1100–1105. https://doi.org/10.1016/s0002-9149(00)00703-7.
    Full Text Link to Item
  - Guyton, J. R., M. A. Blazing, J. Hagar, M. L. Kashyap, R. H. Knopp, J. M. McKenney, D. T. Nash, and S. D. Nash. “Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.” Arch Intern Med 160, no. 8 (April 24, 2000): 1177–84. https://doi.org/10.1001/archinte.160.8.1177.
    Full Text Link to Item
  - Bowen, P. H., and J. R. Guyton. “Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol.” Curr Atheroscler Rep 2, no. 1 (January 2000): 58–63. https://doi.org/10.1007/s11883-000-0095-z.
    Full Text Link to Item
  - Guyton, J. R. “Combination drug therapy for combined hyperlipidemia.” Curr Cardiol Rep 1, no. 3 (September 1999): 244–50. https://doi.org/10.1007/s11886-999-0030-z.
    Full Text Link to Item
  - Guyton, J. R., C. A. Dujovne, and D. R. Illingworth. “Dual hepatic metabolism of cerivastatin--clarifications.” Am J Cardiol 84, no. 4 (August 15, 1999): 497.
    Link to Item
  - Guyton, J. R. “Treatment of type III hyperlipoproteinemia.” Am Heart J 138, no. 1 Pt 1 (July 1999): 17–18. https://doi.org/10.1016/s0002-8703(99)70239-5.
    Full Text Link to Item
  - Perris, A. L., A. G. Bartel, C. Maynard, R. Bariciano, K. B. Gates, J. R. Guyton, and G. S. Wagner. “Does a high level of HDL-C cholesterol undo the bad effects of a high LDL-C cholesterol?” N C Med J 60, no. 4 (July 1999): 217–21.
    Link to Item
  - Capuzzi, D. M., J. R. Guyton, J. M. Morgan, A. C. Goldberg, R. A. Kreisberg, O. A. Brusco, and J. Brody. “Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.” Am J Cardiol 82, no. 12A (December 17, 1998): 74U-81U. https://doi.org/10.1016/s0002-9149(98)00731-0.
    Full Text Link to Item
  - Guyton, J. R. “Effect of niacin on atherosclerotic cardiovascular disease.” Am J Cardiol 82, no. 12A (December 17, 1998): 18U-23U. https://doi.org/10.1016/s0002-9149(98)00767-x.
    Full Text Link to Item
  - Guyton, J. R. “Advances in dyslipidemia: Discussion session II.” American Journal of Cardiology 82, no. 12 A (December 17, 1998): 85U-86U. https://doi.org/10.1016/S0002-9149(98)00956-4.
    Full Text
  - Guyton, J. R., and D. M. Capuzzi. “Treatment of hyperlipidemia with combined niacin-statin regimens.” Am J Cardiol 82, no. 12A (December 17, 1998): 82U-84U. https://doi.org/10.1016/s0002-9149(98)00955-2.
    Full Text Link to Item
  - Kwiterovich, J., and J. R. Guyton. “Introduction.” American Journal of Cardiology 82, no. 12 A (December 17, 1998). https://doi.org/10.1016/S0002-9149(98)00951-5.
    Full Text
  - Morgan, J. M., D. M. Capuzzi, and J. R. Guyton. “A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.” Am J Cardiol 82, no. 12A (December 17, 1998): 29U-34U. https://doi.org/10.1016/s0002-9149(98)00732-2.
    Full Text Link to Item
  - Bales, C. W., K. L. Moreno, J. R. Guyton, P. A. Yunker, M. K. McGee, K. L. Currie, S. Brown, M. Kuchibhatla, and M. K. Drezner. “Comparison of proximate composition and fatty acid and cholesterol content of lean and typical commercial pork.” J Am Diet Assoc 98, no. 11 (November 1998): 1328–30. https://doi.org/10.1016/S0002-8223(98)00297-1.
    Full Text Link to Item
  - Guyton, J. R., A. C. Goldberg, R. A. Kreisberg, D. L. Sprecher, H. R. Superko, and C. M. O’Connor. “Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.” Am J Cardiol 82, no. 6 (September 15, 1998): 737–43. https://doi.org/10.1016/s0002-9149(98)00448-2.
    Full Text Link to Item
  - Matthew, W. D., J. R. Guyton, B. L. Scott, and W. J. Strittmatter. “Apolipoprotein E and neural survival.” Experimental Neurology 151, no. 1 (May 1, 1998): 151–52.
    Link to Item
  - Guyton, J. R., S. E. Miller, M. E. Martin, W. A. Khan, A. D. Roses, and W. J. Strittmatter. “Novel large apolipoprotein E-containing lipoproteins of density 1.006-1.060 g/ml in human cerebrospinal fluid.” J Neurochem 70, no. 3 (March 1998): 1235–40. https://doi.org/10.1046/j.1471-4159.1998.70031235.x.
    Full Text Link to Item
  - Guyton, J. R., C. M. O’Connor, A. C. Goldberg, R. A. Kreisberg, D. L. Sprecher, and H. R. Superko. “1.P.188 Extended-release niacin with or without inhibitors of hydroxymethylglutaryl CoA reductase: Improvement in dyslipidemia with minimal effect on transaminases.” Atherosclerosis 134, no. 1–2 (October 1997): 56–56. https://doi.org/10.1016/s0021-9150(97)88367-0.
    Full Text
  - Thompson, P. D., J. M. Zmuda, L. J. Domalik, R. J. Zimet, J. Staggers, and J. R. Guyton. “Lovastatin increases exercise-induced skeletal muscle injury.” Metabolism 46, no. 10 (October 1997): 1206–10. https://doi.org/10.1016/s0026-0495(97)90218-3.
    Full Text Link to Item
  - Barbeau, M. L., K. F. Klemp, J. R. Guyton, and K. A. Rogers. “Dietary fish oil. Influence on lesion regression in the porcine model of atherosclerosis.” Arterioscler Thromb Vasc Biol 17, no. 4 (April 1997): 688–94. https://doi.org/10.1161/01.atv.17.4.688.
    Full Text Link to Item
  - Kenar, J. A., C. M. Havrilla, N. A. Porter, J. R. Guyton, S. A. Brown, K. F. Klemp, and E. Selinger. “Identification and quantification of regioisomeric cholesteryl linoleate hydroperoxides in oxidized human low density lipoprotein and high density lipoprotein.” Chem Res Toxicol 9, no. 4 (June 1996): 737–44. https://doi.org/10.1021/tx9600098.
    Full Text Link to Item
  - Guyton, J. R., and K. F. Klemp. “Development of the lipid-rich core in human atherosclerosis.” Arterioscler Thromb Vasc Biol 16, no. 1 (January 1996): 4–11. https://doi.org/10.1161/01.atv.16.1.4.
    Full Text Link to Item
  - Guyton, J. R., M. L. Lenz, B. Mathews, H. Hughes, D. Karsan, E. Selinger, and C. V. Smith. “Toxicity of oxidized low density lipoproteins for vascular smooth muscle cells and partial protection by antioxidants.” Atherosclerosis 118, no. 2 (December 1995): 237–49. https://doi.org/10.1016/0021-9150(95)05610-6.
    Full Text Link to Item
  - Bales, C., K. Moreno, S. Brown, J. Guyton, M. McGee, K. Currie, and M. Drezner. “Lean Pork for Lipid-lowering Diets. A Comparison with Traditional Pork.” Journal of the American Dietetic Association 95, no. 9 SUPPL. (September 1, 1995). https://doi.org/10.1016/S0002-8223(95)00545-5.
    Full Text
  - Burlet, O., C. Y. Yang, J. R. Guyton, and S. J. Gaskell. “Tandem mass spectrometric characterization of a specific cysteic acid residue in oxidized human apoprotein B-100.” Journal of the American Society for Mass Spectrometry 6, no. 4 (January 1, 1995): 242–47. https://doi.org/10.1016/1044-0305(94)00098-K.
    Full Text
  - Guyton, J. R. “The role of lipoproteins in atherogenesis.” Adv Exp Med Biol 369 (1995): 29–38. https://doi.org/10.1007/978-1-4615-1957-7_4.
    Full Text Link to Item
  - Guyton, J. R. “The arterial wall and the atherosclerotic lesion.” Curr Opin Lipidol 5, no. 5 (October 1994): 376–81. https://doi.org/10.1097/00041433-199410000-00010.
    Full Text Link to Item
  - Valentinova, N. V., Z. W. Gu, M. Yang, E. V. Yanushevskaya, I. V. Antonov, J. R. Guyton, C. V. Smith, A. M. Gotto, and C. Y. Yang. “Immunoreactivity of apolipoprotein B-100 in oxidatively modified low density lipoprotein.” Biol Chem Hoppe Seyler 375, no. 10 (October 1994): 651–58. https://doi.org/10.1515/bchm3.1994.375.10.651.
    Full Text Link to Item
  - Guyton, J. R., and K. F. Klemp. “Development of the atherosclerotic core region. Chemical and ultrastructural analysis of microdissected atherosclerotic lesions from human aorta.” Arterioscler Thromb 14, no. 8 (August 1994): 1305–14. https://doi.org/10.1161/01.atv.14.8.1305.
    Full Text Link to Item
  - Hughes, H., B. Mathews, M. L. Lenz, and J. R. Guyton. “Cytotoxicity of oxidized LDL to porcine aortic smooth muscle cells is associated with the oxysterols 7-ketocholesterol and 7-hydroxycholesterol.” Arterioscler Thromb 14, no. 7 (July 1994): 1177–85. https://doi.org/10.1161/01.atv.14.7.1177.
    Full Text Link to Item
  - Stary, H. C., A. B. Chandler, S. Glagov, J. R. Guyton, W. Insull, M. E. Rosenfeld, S. A. Schaffer, C. J. Schwartz, W. D. Wagner, and R. W. Wissler. “A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association.” Circulation 89, no. 5 (May 1994): 2462–78. https://doi.org/10.1161/01.cir.89.5.2462.
    Full Text Link to Item
  - Stary, H. C., A. B. Chandler, S. Glagov, J. R. Guyton, W. Insull, M. E. Rosenfeld, S. A. Schaffer, C. J. Schwartz, W. D. Wagner, and R. W. Wissler. “A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association.” Arterioscler Thromb 14, no. 5 (May 1994): 840–56. https://doi.org/10.1161/01.atv.14.5.840.
    Full Text Link to Item
  - Daley, S. J., K. F. Klemp, J. R. Guyton, and K. A. Rogers. “Cholesterol-fed and casein-fed rabbit models of atherosclerosis. Part 2: Differing morphological severity of atherogenesis despite matched plasma cholesterol levels.” Arterioscler Thromb 14, no. 1 (January 1994): 105–41. https://doi.org/10.1161/01.atv.14.1.105.
    Full Text Link to Item
  - Siegel, C. O., D. A. Churchill, L. Vu, J. R. Guyton, S. T. Minor, and A. E. Raizner. “Amiprilose hydrochloride inhibits porcine aortic smooth muscle cell proliferation in vitro.” Artery 21, no. 2 (1994): 114–23.
    Link to Item
  - Guyton, J. R., and K. F. Klemp. “Transitional features in human atherosclerosis. Intimal thickening, cholesterol clefts, and cell loss in human aortic fatty streaks.” Am J Pathol 143, no. 5 (November 1993): 1444–57.
    Link to Item
  - Yang, C. Y., Z. W. Gu, N. Valentinova, H. J. Pownall, B. Lee, M. Yang, Y. H. Xie, J. R. Guyton, T. N. Vlasik, and J. C. Fruchart. “Human very low density lipoprotein structure: interaction of the C apolipoproteins with apolipoprotein B-100.” J Lipid Res 34, no. 8 (August 1993): 1311–21.
    Link to Item
  - Guyton, J. R., and K. F. Klemp. “Early extracellular and cellular lipid deposits in aorta of cholesterol-fed rabbits.” Am J Pathol 141, no. 4 (October 1992): 925–36.
    Link to Item
  - Rodgers, G. P., S. T. Minor, K. Robinson, D. Cromeens, L. C. Stephens, S. C. Woolbert, J. R. Guyton, K. Wright, R. Siegel, and G. S. Roubin. “The coronary artery response to implantation of a balloon-expandable flexible stent in the aspirin- and non-aspirin-treated swine model.” Am Heart J 122, no. 3 Pt 1 (September 1991): 640–47. https://doi.org/10.1016/0002-8703(91)90506-d.
    Full Text Link to Item
  - Guyton, J. R., K. F. Klemp, and M. P. Mims. “Altered ultrastructural morphology of self-aggregated low density lipoproteins: coalescence of lipid domains forming droplets and vesicles.” J Lipid Res 32, no. 6 (June 1991): 953–62.
    Link to Item
  - Podet, E. J., D. R. Shaffer, S. H. Gianturco, W. A. Bradley, C. Y. Yang, and J. R. Guyton. “Interaction of low density lipoproteins with human aortic elastin.” Arterioscler Thromb 11, no. 1 (January 1991): 116–22. https://doi.org/10.1161/01.atv.11.1.116.
    Full Text Link to Item
  - Guyton, J. R., B. L. Black, and C. L. Seidel. “Focal toxicity of oxysterols in vascular smooth muscle cell culture. A model of the atherosclerotic core region.” Am J Pathol 137, no. 2 (August 1990): 425–34.
    Link to Item
  - Guyton, J. R., K. F. Klemp, B. L. Black, and T. M. Bocan. “Extracellular lipid deposition in atherosclerosis.” Eur Heart J 11 Suppl E (August 1990): 20–28. https://doi.org/10.1093/eurheartj/11.suppl_e.20.
    Full Text Link to Item
  - Rodgers, G. P., S. T. Minor, K. Robinson, D. Cromeens, S. C. Woolbert, L. C. Stephens, J. R. Guyton, K. Wright, G. S. Roubin, and A. E. Raizner. “Adjuvant therapy for intracoronary stents. Investigations in atherosclerotic swine.” Circulation 82, no. 2 (August 1990): 560–69. https://doi.org/10.1161/01.cir.82.2.560.
    Full Text Link to Item
  - Lenz, M. L., H. Hughes, J. R. Mitchell, D. P. Via, J. R. Guyton, A. A. Taylor, A. M. Gotto, and C. V. Smith. “Lipid hydroperoxy and hydroxy derivatives in copper-catalyzed oxidation of low density lipoprotein.” J Lipid Res 31, no. 6 (June 1990): 1043–50.
    Link to Item
  - Guyton, J. R., D. T. Dao, K. L. Lindsay, and A. A. Taylor. “Ultrastructure of hypertensive rat aorta. Increased basement membrane-like material.” Hypertension 15, no. 1 (January 1990): 56–67. https://doi.org/10.1161/01.hyp.15.1.56.
    Full Text Link to Item
  - Cushing, G. L., J. W. Gaubatz, M. L. Nava, B. J. Burdick, T. M. Bocan, J. R. Guyton, D. Weilbaecher, M. E. DeBakey, G. M. Lawrie, and J. D. Morrisett. “Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation.” Arteriosclerosis 9, no. 5 (September 1989): 593–603. https://doi.org/10.1161/01.atv.9.5.593.
    Full Text Link to Item
  - Guyton, J. R., D. R. Shaffer, and P. D. Henry. “Stress fibers in endothelial cells overlying atherosclerotic lesions in rabbit aorta.” Am J Med Sci 298, no. 2 (August 1989): 79–82. https://doi.org/10.1097/00000441-198908000-00002.
    Full Text Link to Item
  - Guyton, J. R., and K. F. Klemp. “The lipid-rich core region of human atherosclerotic fibrous plaques. Prevalence of small lipid droplets and vesicles by electron microscopy.” Am J Pathol 134, no. 3 (March 1989): 705–17.
    Link to Item
  - Guyton, J. R., and K. F. Klemp. “Ultrastructural discrimination of lipid droplets and vesicles in atherosclerosis: value of osmium-thiocarbohydrazide-osmium and tannic acid-paraphenylenediamine techniques.” J Histochem Cytochem 36, no. 10 (October 1988): 1319–28. https://doi.org/10.1177/36.10.2458408.
    Full Text Link to Item
  - Bocan, T. M., S. A. Brown, and J. R. Guyton. “Human aortic fibrolipid lesions. Immunochemical localization of apolipoprotein B and apolipoprotein A.” Arteriosclerosis 8, no. 5 (September 1988): 499–508. https://doi.org/10.1161/01.atv.8.5.499.
    Full Text Link to Item
  - Gaubatz, J. W., M. V. Chari, M. L. Nava, J. R. Guyton, and J. D. Morrisett. “Isolation and characterization of the two major apoproteins in human lipoprotein [a].” J Lipid Res 28, no. 1 (January 1987): 69–79.
    Link to Item
  - Morrisett, J. D., J. R. Guyton, J. W. Gaubatz, and A. M. Gotto. “Lipoprotein(a): Structure, Metabolism and Epidemiology.” New Comprehensive Biochemistry 14, no. C (January 1, 1987): 129–52. https://doi.org/10.1016/S0167-7306(08)60198-2.
    Full Text
  - Dahlen, G. H., J. R. Guyton, M. Attar, J. A. Farmer, J. A. Kautz, and A. M. Gotto. “Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography.” Circulation 74, no. 4 (October 1986): 758–65. https://doi.org/10.1161/01.cir.74.4.758.
    Full Text Link to Item
  - Ahmad, T. Y., J. R. Guyton, J. T. Sparrow, and J. D. Morrisett. “Apolipoprotein C-III/sphingomyelin recombinants: formation, isolation, and characterization.” Biochemistry 25, no. 15 (July 29, 1986): 4407–14. https://doi.org/10.1021/bi00363a035.
    Full Text Link to Item
  - Bocan, T. M., T. A. Schifani, and J. R. Guyton. “Ultrastructure of the human aortic fibrolipid lesion. Formation of the atherosclerotic lipid-rich core.” Am J Pathol 123, no. 3 (June 1986): 413–24.
    Link to Item
  - Mims, M. P., J. R. Guyton, and J. D. Morrisett. “Microemulsions of cholesteryl oleate and dimyristoylphosphatidylcholine: a model for cholesteryl ester rich very low density lipoproteins.” Biochemistry 25, no. 2 (January 28, 1986): 474–83. https://doi.org/10.1021/bi00350a030.
    Full Text Link to Item
  - Guyton, J. R., T. M. Bocan, and T. A. Schifani. “Quantitative ultrastructural analysis of perifibrous lipid and its association with elastin in nonatherosclerotic human aorta.” Arteriosclerosis 5, no. 6 (November 1985): 644–52. https://doi.org/10.1161/01.atv.5.6.644.
    Full Text Link to Item
  - Bocan, T. M., and J. R. Guyton. “Human aortic fibrolipid lesions. Progenitor lesions for fibrous plaques, exhibiting early formation of the cholesterol-rich core.” Am J Pathol 120, no. 2 (August 1985): 193–206.
    Link to Item
  - Guyton, J. R., G. H. Dahlen, W. Patsch, J. A. Kautz, and A. M. Gotto. “Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B.” Arteriosclerosis 5, no. 3 (May 1985): 265–72. https://doi.org/10.1161/01.atv.5.3.265.
    Full Text Link to Item
  - Guyton, J. R., and C. J. Hartley. “Flow restriction of one carotid artery in juvenile rats inhibits growth of arterial diameter.” Am J Physiol 248, no. 4 Pt 2 (April 1985): H540–46. https://doi.org/10.1152/ajpheart.1985.248.4.H540.
    Full Text Link to Item
  - Bocan, T. M. A., J. R. Guyton, and T. A. Schifani. “Human aortic fibro-lipid lesions: Cholesterol-rich core formation in a fibrous plaque precursor lesion.” Federation Proceedings 44, no. 4 (January 1, 1985).
  - Guyton, J. R., T. M. A. Bocan, and T. A. Schifano. “Ultrastructural localization of perifibrous lipid in grossly normal human aortic intima - Role of elastin.” Federation Proceedings 44, no. 4 (January 1, 1985).
  - Guyton, J. R., and C. J. Hartley. “Flow restriction of one carotid artery in juvenile rats inhibits growth of arterial diameter.” American Journal of Physiology Heart and Circulatory Physiology 17, no. 4 (January 1, 1985).
  - Guyton, J. R. “Locational stereology performed within sampling fields in rat aortic wall, a polarized tissue.” J Microsc 135, no. Pt 1 (July 1984): 103–14. https://doi.org/10.1111/j.1365-2818.1984.tb04653.x.
    Full Text Link to Item
  - Guyton, J. R., D. T. Dao, and K. L. Lindsay. “Endothelial denudation and myointimal thickening in the rat carotid artery induced by the passage of bubbles.” Exp Mol Pathol 40, no. 3 (June 1984): 340–48. https://doi.org/10.1016/0014-4800(84)90051-0.
    Full Text Link to Item
  - Guyton, J. R., and C. J. Hartley. “Effects of flow restriction and reduced velocity pulsation on circumferential arterial growth.” Federation Proceedings 43, no. 4 (January 1, 1984).
  - Guyton, J. R., K. L. Lindsay, and D. T. Dao. “Comparison of aortic intima and inner media in young adult versus aging rats. Stereology in a polarized system.” Am J Pathol 111, no. 2 (May 1983): 234–46.
    Link to Item
  - Guyton, J. R. “Smooth muscle growth and cholesterol accumulation in atherogenesis.” Int Rev Physiol 26 (1982): 1–49.
    Link to Item
  - Gordon, D., J. R. Guyton, and M. J. Karnovsky. “Intimal alterations in rat aorta induced by stressful stimuli.” Lab Invest 45, no. 1 (July 1981): 14–27.
    Link to Item
  - Guyton, J. R., R. D. Rosenberg, A. W. Clowes, and M. J. Karnovsky. “Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin.” Circ Res 46, no. 5 (May 1980): 625–34. https://doi.org/10.1161/01.res.46.5.625.
    Full Text Link to Item
  - Guyton, J. R., and M. J. Karnovsky. “Smooth muscle cell proliferation in the occluded rat carotid artery: lack of requirement for luminal platelets.” Am J Pathol 94, no. 3 (March 1979): 585–602.
    Link to Item
  - Guyton, J. R., J. S. Soeldner, J. Giner, C. K. Colton, and R. S. Morris. “The development of an implantable electrochemical glucose sensor: response to glucose in bovine serum ultrafiltrate.” Horm Metab Res Suppl, no. 8 (1979): 24–26.
    Link to Item
  - Guyton, J. R., R. O. Foster, J. S. Soeldner, M. H. Tan, C. B. Kahn, L. Koncz, and R. E. Gleason. “A model of glucose-insulin homeostasis in man that incorporates the heterogeneous fast pool theory of pancreatic insulin release.” Diabetes 27, no. 10 (October 1978): 1027–42. https://doi.org/10.2337/diab.27.10.1027.
    Full Text Link to Item
  - Guyton, J. R., and J. T. Willerson. “Peripheral venous platelet aggregates in patients with unstable angina pectoris and acute myocardial infarction.” Angiology 28, no. 10 (1977): 695–701.
  - Guyton, J. R. “Letter: Role of reverse transcriptase.” N Engl J Med 294, no. 16 (April 15, 1976): 902–3. https://doi.org/10.1056/NEJM197604152941615.
    Full Text Link to Item
  - Guyton, J. R., K. W. Chang, S. Aisenberg, and J. S. Soeldner. “Activity of various endogenous compounds and pharmacologic agents at a glucose-oxidizing platinum electrode.” Med Instrum 9, no. 5 (September 1975): 227–32.
    Link to Item
  - Guyton, J. R., and R. E. Zumwalt. “Letter: Pneumococcemia with sarcoid-infiltrated spleen.” Ann Intern Med 82, no. 6 (June 1975): 847–48. https://doi.org/10.7326/0003-4819-82-6-847.
    Full Text Link to Item
  - Foster, R. O., J. S. Soeldner, M. H. Tan, and J. R. Guyton. “Short ten glucose homeostasis in ian: A systems opamics model.” Journal of Dynamic Systems, Measurement and Control, Transactions of the Asme 95, no. 3 (January 1, 1973): 308–14. https://doi.org/10.1115/1.3426720.
    Full Text
  - Gann, D. S., F. E. Yates, D. J. Marsh, S. W. Smith, M. Ookhtens, R. N. Bergman, E. W. Kraegen, et al. “REGULATION AND CONTROL IN PHYSIOLOGICAL SYSTEMS.,” January 1, 1973.
  - Gann, D. S., F. E. Yates, D. J. Marsh, S. W. Smith, M. Ookhtens, R. N. Bergman, E. W. Kraegen, et al. “REGULATION AND CONTROL IN PHYSIOLOGICAL SYSTEMS.,” n.d.
- Book Sections
  - Guyton, J. R., K. B. Campbell, and W. C. Lakey. “Niacin: Risk benefits and role in treating dyslipidemias,” 1:439–52, 2015. https://doi.org/10.1007/978-1-60761-424-1_26.
    Full Text
  - Guyton, J. R. “Disorders of lipid and lipoprotein metabolism.” In Garner and Klintworth’s Pathobiology of Ocular Disease Part B, Third Edition, 1019–36, 2007.
- Conference Papers
  - Ginsberg, Henry N., Daniel J. Rader, Frederick J. Raal, John R. Guyton, Christelle Lorenzato, Robert Pordy, Marie T. Baccara-Dinet, and Eric S. Stroes. “ODYSSEY HIGH FH: Efficacy and Safety of Alirocumab in Patients With Severe Heterozygous Familial Hypercholesterolemia.” In Circulation, 130:2119–2119. LIPPINCOTT WILLIAMS & WILKINS, 2014.
    Link to Item
  - Moriarty, Patrick M., Paul D. Thompson, Christopher P. Cannon, John R. Guyton, Jean Bergeron, Franklin J. Zieve, Eric Bruckert, et al. “ODYSSEY ALTERNATIVE: Efficacy And Safety of the Proprotein Convertase Subtilisin/kexin Type 9 Monoclonal Antibody, Alirocumab, versus Ezetimibe, in Patients With Statin Intolerance as Defined by a Placebo Run-in and Statin Rechallenge Arm.” In Circulation, 130:2108–9. LIPPINCOTT WILLIAMS & WILKINS, 2014.
    Link to Item
  - Farnier, M., J. R. Guyton, E. Jensen, A. Polis, A. O. Johnson-Levonas, and P. Brudi. “Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.” In European Heart Journal, 33:281–82. OXFORD UNIV PRESS, 2012.
    Link to Item
  - Betteridge, J., J. R. Guyton, M. Farnier, L. A. Leiter, J. Lin, A. Shah, A. O. Johnson-Levonas, and P. Brudi. “Greater dissociation of apolipoprotein B and LDL cholesterol targets in diabetes versus non-diabetes patients receiving lipid-lowering therapy.” In Diabetologia, 54:S278–S278. SPRINGER, 2011.
    Link to Item
  - Betteridqe, J., J. R. Guyton, M. Farmer, L. A. Leiter, J. Lin, A. Shah, A. O. Johnson-Levonas, and P. Brudi. “781 MORE AGGRESSIVE LDL-C AND NON-HDL-C TARGETS MUST BE ACHIEVED IN PATIENTS RECEIVING LIPID-LOWERING THERAPY TO NORMALIZE APOB-CONTAINING LIPOPROTEINS.” In Atherosclerosis Supplements, 12:163–64. Elsevier BV, 2011. https://doi.org/10.1016/s1567-5688(11)70782-6.
    Full Text
  - Brown, W. V., S. Fazio, J. R. Guyton, Q. Dong, J. E. Tomassini, A. Shah, and A. M. Tershakovec. “59 RELATIONSHIPS BETWEEN HSCRP REDUCTION AND LDL-C, NONHDL-C, APOB AND HDL-C IN HYPERLIPIDEMIC PATIENTS TREATED WITH EZETIMIBE/SIMVASTATIN + EXTENDED-RELEASE NIACIN.” In Atherosclerosis Supplements, 12:14–14. Elsevier BV, 2011. https://doi.org/10.1016/s1567-5688(11)70060-5.
    Full Text
  - Fazio, S., J. R. Guyton, J. Lin, J. E. Tomassini, A. Shah, and A. M. Tershakovec. “82 COMBINATION EZETIMIBE/SIMVASTATIN + EXTENDED-RELEASE NIACIN THERAPY IMPROVES ATTAINMENT OF RECOMMENDED LDL-C, NON-HDL-C AND APOB LEVELS IN HYPERLIPIDEMIC PATIENTS.” In Atherosclerosis Supplements, 12:20–20. Elsevier BV, 2011. https://doi.org/10.1016/s1567-5688(11)70083-6.
    Full Text
  - Benjamin, A., S. Suchindran, K. Pearce, J. Rowell, L. F. Lien, J. R. Guyton, and J. J. McCarthy. “Gene by Sex Interaction for Body Mass Index in the Framingham Heart Study.” In Endocrine Reviews, Vol. 31. ENDOCRINE SOC, 2010.
    Link to Item
  - Li, J. H., X. Q. Lao, H. Tillmann, J. Rowell, K. Patel, A. J. Thompson, S. Suchindran, et al. “1179 INTERFERON LAMBDA GENOTYPE AND LOW SERUM LDL CHOLESTEROL LEVELS IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION.” In Journal of Hepatology, 52:S456–S456. Elsevier BV, 2010. https://doi.org/10.1016/s0168-8278(10)61180-4.
    Full Text
  - Rowell, Jennifer V., Alexander J. Thompson, Keyur Patel, Xiang Q. Lao, Sunil Suchindran, John R. Guyton, John G. McHutchison, and Jeanette McCarthy. “SERUM APOLIPOPROTEIN CIII LEVELS ARE INDEPENDENTLY ASSOCIATED WITH HEPATIC FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION.” In Hepatology, 50:1052A-1052A. JOHN WILEY & SONS INC, 2009.
    Link to Item
  - Guyton, John R. “Understanding and Preventing Atherosclerosis.” In Menopause the Journal of the North American Menopause Society, 15:1200–1200. LIPPINCOTT WILLIAMS & WILKINS, 2008.
    Link to Item
  - Guyton, J. R., B. G. Brown, S. Fazio, J. Lin, A. Polis, J. E. Tomassini, A. Shah, and A. M. Tershakovec. “Effect of ezetimibe/simvastatin (E/S) plus extended-release niacin (N) in type IIa and IIb hyperlipidaemia (HL) patients with diabetes (DM) or metabolic syndrome (MS).” In Diabetologia, 51:S339–41. SPRINGER, 2008.
    Link to Item
  - Goldberg, R. B., J. R. Guyton, T. Mazzone, R. S. Weinstock, A. Polis, J. E. Tomassini, and A. M. Tershakovec. “PO23-786 ASSOCIATION BETWEEN BASELINE LDL-C, TRIGLYCERIDES, AND HDL-C LEVELS AND THE LIPID-ALTERING AND HS-CRP EFFICACIES OF EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN IN TYPE 2 DIABETES PATIENTS: THE VYTAL STUDY.” In Atherosclerosis Supplements, 8:209–209. Elsevier BV, 2007. https://doi.org/10.1016/s1567-5688(07)71796-8.
    Full Text
  - Guyton, J. R., R. B. Goldberg, T. Mazzone, R. S. Weinstock, A. Polis, E. Rosenberg, P. Edwards, and A. M. Tershakovec. “PO23-755 EZETIMIBE/SIMVASTATIN MORE FAVORABLY INFLUENCES LIPOPROTEIN/APOLIPOPROTEIN RATIOS THAN ATORVASTATIN MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES.” In Atherosclerosis Supplements, 8:201–201. Elsevier BV, 2007. https://doi.org/10.1016/s1567-5688(07)71765-8.
    Full Text
  - Guyton, J. R., R. S. Weinstock, T. Mazzone, R. B. Goldberg, A. Polis, E. Rosenberg, and A. M. Tershakovec. “PO23-734 INFLUENCE OF AGE, GENDER, AND ETHNICITY ON TREATMENT EFFECTS IN THE VYTAL TRIAL OF EZETIMIBE/SIMVASTATIN VS. ATORVASTATIN IN TYPE 2 DIABETICS.” In Atherosclerosis Supplements, 8:195–96. Elsevier BV, 2007. https://doi.org/10.1016/s1567-5688(07)71744-0.
    Full Text
  - Weinstock, R. S., R. B. Goldberg, J. R. Guyton, T. Mazzone, A. Polis, J. E. Tomassini, E. Desrosiers, and A. M. Tershakovec. “PO23-777 EFFECT OF EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN ON ATTAINING RECOMMENDED LEVELS OF LDL-C, APOLIOPROTEIN B, NON-HDL-C AND HS-CRP IN TYPE 2 DIABETES.” In Atherosclerosis Supplements, 8:207–207. Elsevier BV, 2007. https://doi.org/10.1016/s1567-5688(07)71787-7.
    Full Text
  - Mazzone, T., R. B. Goldberg, J. R. Guyton, R. S. Weinstock, A. Polis, R. A. Gazzara, J. E. Tomassini, and A. M. Tershakovec. “The safety and efficacy of ezetimibe/simvastatin (E/S) versus atorvastatin (A) in hypercholesterolaemic (HC) patients with type 2 diabetes (T2DM).” In Diabetologia, 49:748–748. SPRINGER, 2006.
    Link to Item
  - Guyton, J. R. “Su-S1:2 The neurological system and statin safety.” In Atherosclerosis Supplements, 7:1–1. Elsevier BV, 2006. https://doi.org/10.1016/s1567-5688(06)80002-4.
    Full Text
  - Chiou, P., A. M. Xydakis, J. R. Guyton, J. L. Stein, P. H. Jones, and C. M. Ballantyne. “Efficacy and tolerability of ezetimibe add-on therapy in bile acid sequestrant/niacin-based regimen.” In Arteriosclerosis Thrombosis and Vascular Biology, 24:E82–E82. LIPPINCOTT WILLIAMS & WILKINS, 2004.
    Link to Item
  - GUYTON, J. R., and K. F. KLEMP. “SPECIFIC FEATURES OF LIPID DEPOSITS ASSOCIATED WITH ARTERIAL COLLAGEN AND ELASTIN.” In Atherosclerosis X, edited by F. P. Woodford, J. Davignon, and A. Sniderman, 1066:360–64. ELSEVIER SCIENCE PUBL B V, 1995.
    Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

In the News

Selected Grants

External Relationships

Selected Publications

Academic Articles

Book Sections

Conference Papers